

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2007

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2007				
<i>(Rs. in thousands)</i>				
Sr. No.	Particulars	Quarter ended 30.06.2007 (Audited)	Quarter ended 30.06.2006 (Audited)	Year ended 31.03.2007 (Audited)
1.	Net Sales	2,274,032	1,836,973	8,509,754
2.	Other Income	41,869	14,285	121,105
3.	Total Expenditure (a+b+c+d+e)	1,688,771	1,429,275	6,266,690
	a. (Increase)/decrease in stock in trade	(166,774)	(45,383)	(218,877)
	b. Consumption of Raw Materials	1,143,574	1,054,881	4,377,002
	c. Power cost	204,287	101,849	620,715
	d. Employee cost	194,728	117,140	618,055
	e. Other Expenses	312,956	200,788	869,795
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	627,130	421,983	2,364,169
5.	Interest and finance charges	8,925	16,570	77,618
6.	Depreciation	162,963	90,161	576,060
7.	Profit Before Taxation (4-5-6)	455,242	315,252	1,710,491
8.	Provision for current tax (including Fringe Benefit Tax)	15,100	42,112	9,158
9.	Provision for deferred tax	(8,472)	(2,585)	117,831
10.	Net Profit (7-8-9)	448,614	275,725	1,583,502
11.	Paid-up equity share capital	500,000	500,000	500,000
12.	Reserves excluding revaluation reserves	9,379,095	7,797,704	8,905,315
13.	Earnings per share (Par value of Rs. 5/-)			
	- Basic-(in Rs.)	4.64	2.86	16.38
	- Diluted-(in Rs.)	4.49	2.85	16.30
14.	Aggregate of Non-Promoter Shareholding			
	- Number of Shares	39,884,842	39,884,842	39,884,842
	- Percentage of shareholding	39.88%	39.88%	39.88%

SEGMENT REPORTING FOR THE QUARTER ENDED JUNE 30, 2007				
<i>(Rs. in thousands)</i>				
Sr. No.	Particulars	Quarter ended 30.06.2007 (Audited)	Quarter ended 30.06.2006 (Audited)	Year ended 31.03.2007 (Audited)
1.	Segment revenue			
	a. Enzymes	224,605	241,477	1,015,022
	b. Pharma	2,062,047	1,619,041	7,559,610
	c. Unallocated	196,253	-	350,229
	Total	2,482,905	1,860,518	8,924,861
	Less: Inter-segment revenue	173,041	23,545	356,243
	Net sales/Income from operations	2,309,864	1,836,973	8,568,618
2.	Segment results			
	Profit before interest, depreciation and tax from each segment			
	a. Enzymes	30,762	107,011	372,430
	b. Pharma	818,559	612,956	2,400,124
	c. Unallocated	59,204	-	112,656
	Total	908,525	719,967	2,885,210
	Less: Interest	8,925	16,570	77,618
	Depreciation	162,963	90,161	576,060
	Unallocated corporate expenses net of unallocable income	281,395	297,984	521,041
	Profit before tax	455,242	315,252	1,710,491
3.	Capital employed			
	a. Enzymes	499,383	451,971	724,575
	b. Pharma	7,286,595	7,791,584	7,319,980
	c. Unallocable corporate assets	4,188,248	1,941,757	3,085,007
	Less: Corporate liabilities	2,084,441	1,875,312	1,713,157
	Total capital employed	9,889,785	8,310,000	9,416,405
	Less: Revaluation Reserve	10,690	12,296	11,090
	Capital employed net of revaluation reserves	9,879,095	8,297,704	9,405,315

Note: 1. The primary reporting of the Company has been performed on the basis of business segment. The Company is organised into two business segments, enzymes and active pharmaceutical ingredients ('Pharma'). Segments have been identified and reported based on the nature of the products, the risks and returns, the organisation structure and the internal financial reporting systems. 2. The income, expense, assets and liabilities pertaining to Biocon Park Developer have been included under "unallocated". 3. The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter ended June 30, 2007

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2007				
<i>(Rs. in thousands)</i>				
Sr. No.	Particulars	Quarter ended 30.06.2007 (Audited)	Quarter ended 30.06.2006 (Audited)	Year ended 31.03.2007 (Audited)
1.	Net Sales	2,708,307	2,115,089	9,857,311
2.	Other Income	9,892	13,585	38,183
3.	Total Expenditure (a+b+c+d+e)	1,945,225	1,576,482	7,022,480
	a. (Increase)/decrease in stock in trade	(189,713)	(45,383)	(218,877)
	b. Consumption of Raw Materials	1,279,892	1,123,876	4,726,637
	c. Power cost	205,081	108,493	619,567
	d. Employee cost	297,485	180,256	934,899
	e. Other Expenses	352,480	209,240	960,254
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	772,974	552,192	2,873,014
5.	Interest and finance charges	27,539	16,710	97,563
6.	Depreciation	216,397	109,639	665,483
7.	Profit Before Taxation (4-5-6)	529,038	425,843	2,109,968
8.	Provision for current tax (including Fringe Benefit Tax)	40,388	46,086	18,133
9.	Provision for deferred tax	(25,599)	(3,954)	150,986
10.	Net Profit before minority interest (7-8-9)	514,249	383,711	1,940,849
11.	Add/(Less): Minority interest	14,119	5,394	61,767
12.	Net Profit (10+11)	528,368	389,105	2,002,616
13.	Paid-up equity share capital	500,000	500,000	500,000
14.	Reserves excluding revaluation reserves	10,728,518	8,761,634	10,174,980
15.	Earnings per share (Par value of Rs 5/-)			
	- Basic -(in Rs.)	5.47	4.04	20.72
	- Diluted-(in Rs.)	5.28	4.02	20.62

Notes: 1. The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in India and comply with the Accounting Standard (AS 21) on Consolidated Financial Statements, issued by the Institute of Chartered Accountants of India to reflect the financial position and the results of operations of Biocon together with its subsidiary companies, Syngene, Clinigene and JV company, Biocon Biopharmaceuticals. 2. The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter ended June 30, 2007

Notes:

- The Company entered into a definitive agreement to divest its Enzymes business vertical to a party for a consideration of Rs. 4,670 million. This transaction, subject to shareholder and regulatory approvals, is expected to be completed by the end of the 3rd Quarter of FY 2008.
- The earnings considered in ascertaining the Company's earnings per share comprise of the net profit after tax. The number of shares used in computing the basic earnings per share is the weighted average number of shares outstanding during the period/year. The number of shares used in computing diluted earnings per share comprises the weighted average share considered for deriving basic earnings per share, and also the weighted average number of shares, if any which would have been issued on the conversion of all dilutive potential equity shares. In accordance with the revised SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 (Revised), the ESOP Trust has been consolidated with the Company.
- Total number of shareholder complaints pending at the beginning of the quarter was Nil. Complaints received during the quarter were 16. All complaints received during the quarter were resolved and there were no complaints pending for redressal as at June 30, 2007
- The above results were reviewed by the Audit committee on July 17, 2007 and then approved by the Board of Directors at their meeting held on July 18, 2007.
- The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter ended June 30, 2007.

For and on behalf of the Board

Sd/-
Kiran Mazumdar-Shaw
 Managing Director

Place: Bangalore Date: July 18, 2007